Patents by Inventor Aristides TAGALAKIS

Aristides TAGALAKIS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11793756
    Abstract: A non-viral delivery complex comprising a cationic core which is a nanoparticle comprising a peptide having a polycationic nucleic acid binding component, a cleavable spacer element and a cell surface receptor binding component; a nucleic acid and optionally a cationic lipid; and an anionic liposomal coating surrounding the cationic core, said coating comprising lipids from a subject's cells. Also related formulations, uses and methods.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: October 24, 2023
    Assignee: UCL Business PLC
    Inventors: Stephen Hart, Aristides Tagalakis
  • Publication number: 20220105192
    Abstract: A nanoparticle complex for delivery to cells comprising an RNA interference agent and a delivery vehicle comprised of a liposome and peptide. The peptide may be transmembrane, at least part of which is located external to the liposome. The delivery vehicle is used to deliver the RNA interference agent to cells. The RNA interference agent may target the activity of E3 ubiquitin ligase Itch. The complex may be used to treat chemotherapy resistant tumours and/or cancers. Also related compositions, combination, kit, methods and uses thereof.
    Type: Application
    Filed: January 15, 2020
    Publication date: April 7, 2022
    Inventors: Simon Newman, Stephen Hart, Aristides TAGALAKIS, Jinhong Meng
  • Patent number: 11098006
    Abstract: A lipid comprising a tri-chain cation having a cationic head group and three or more C7-24 hydrocarbyl groups for use in non-viral gene delivery systems, for example in the formation of lipopolyplex transfection vectors. Exceptionally good nucleic acid transfection is observed when nucleic acid and targeting peptides are formulated with the lipid of the invention (or lipid formulated with a co-lipid) into a LPD complex.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: August 24, 2021
    Assignee: RYBOQUIN COMPANY LTD
    Inventors: Helen Claire Hailes, Alethea Bernice Tabor, Mohn Firouz Mohd Mustapa, Stephen Lewis Hart, Aristides Tagalakis
  • Publication number: 20210052496
    Abstract: A non-viral delivery complex comprising a cationic core which is a nanoparticle comprising a peptide having a polycationic nucleic acid binding component, a cleavable spacer element and a cell surface receptor binding component; a nucleic acid and optionally a cationic lipid; and an anionic liposomal coating surrounding the cationic core, said coating comprising lipids from a subject's cells. Also related formulations, uses and methods.
    Type: Application
    Filed: January 10, 2019
    Publication date: February 25, 2021
    Inventors: Stephen Hart, Aristides Tagalakis
  • Publication number: 20210030891
    Abstract: A method for translocating a cationic micro/nanoparticle across a mucus layer, the method including (a) contacting the mucus layer with at least one alginate oligomer, the alginate oligomer having at least 70% mannuronate residues, together with the cationic micro/nanoparticle; or (b)(i) contacting the cationic micro/nanoparticle with an alginate oligomer having at least 70% mannuronate residues thereby forming a micro/nanoparticle carrying the alginate oligomer, and (b)(ii) contacting the mucus layer with the micro/nanoparticle prepared in step (b)(i).
    Type: Application
    Filed: March 19, 2019
    Publication date: February 4, 2021
    Inventors: Aristides Tagalakis, Stephen Hart, Are Kristiansen, Arne Dessen, Philip D. Rye
  • Publication number: 20190084923
    Abstract: A lipid comprising a tri-chain cation having a cationic head group and three or more C7-24 hydrocarbyl groups for use in non-viral gene delivery systems, for example in the formation of lipopolyplex transfection vectors. Exceptionally good nucleic acid transfection is observed when nucleic acid and targeting peptides are formulated with the lipid of the invention (or lipid formulated with a co-lipid) into a LPD complex.
    Type: Application
    Filed: March 10, 2017
    Publication date: March 21, 2019
    Applicant: RYBOQUIN COMPANY LTD
    Inventors: Helen Claire HAILES, Alethea Bernice TABOR, Mohn Firouz MOHD MUSTAPA, Stephen Lewis HART, Aristides TAGALAKIS